1. Scrip

Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib

 
• By Joseph Haas

Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.

Vitiligo on the hands. Shutterstock 1621981522
Opzelura is the first approved drug therapy for vitiligo • Source: Shutterstock

Incyte Corporation reinvented itself as a dermatology company a few years ago and is building critical mass in that therapeutic area with the US approval on 18 July of Opzelura for vitiligo, less than a year after the topical formulation of ruxolitinib obtained US Food and Drug Administration approval for atopic dermatitis.

The drug is the first approved therapy for vitiligo in the US and is part of a string of advancements in dermatology. Eli Lilly and Company just recently secured the first approval of a systemic JAK inhibitor, Olumiant (baricitinib), for alopecia areata

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.